mundipharma edo gmbh



mundipharma edo gmbh

Homepage, Mundipharma

Mundipharma appoints new Chief Commercial Officers Read More. Covid19 response Read More. The importance of allyship As we embark on a monthlong celebration of Pride, where we come together to recognise the progress made, and ongoing challenges facing the LGBTQ+ community, Marc Princen, CEO shares his views on the importance of allyship.

Mundipharma EDO GmbH shows strong activity in early

Mundipharma EDO GmbH (“EDO”), established at the beginning of 2013, is pleased to announce that it is demonstrating promising early results with its lead small molecule compound EDOS101, which has shown strong activity in treating various haematological malignancies and solid tumours.

Mundipharma EDO GmbH Data Confirm EDOS101 Is

Mundipharma EDO GmbH ("EDO") EDO is developing early stage assets in oncology for the Mundipharma network of independent associated companies and is committed to increasing the treatment options available for cancer patients, improving their quality of life through the early development of small molecules and biologics.

Study of Tinostamustine, FirstinClass Alkylating HDACi

MundipharmaEDO GmbH: ClinicalTrials.gov Identifier: NCT Other Study ID Numbers: EDOS : First Posted: October 15, 2015 Key Record Dates: Last Update Posted: June 2, 2021 Last Verified: May 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes: Plan Description:

Mundipharma EDO GmbH shows strong preclinical activity

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce strong preclinical activity in Multiple Myeloma with its lead small molecule compound EDOS101, presented at the European Haematology Association in Milan in June 2014.(1)

Study of the Safety, Pharmacokinetics and Efficacy of EDO

MundipharmaEDO GmbH: ClinicalTrials.gov Identifier: NCT Other Study ID Numbers: EDOS : First Posted: November 17, 2017 Key Record Dates: Last Update Posted: December 24, 2020 Last Verified: December 2020 Individual Participant Data (IPD) Sharing Statement:

Mundipharma EDO GmbH, Basel Kontakt

Mundipharma EDO GmbH (Mundipharma EDO S.à r.l.) (Mundipharma EDO Ltd. liab. Co.), in Basel, CH270.4.003.8413, St.Alban Rheinweg 74, 4052 Basel, Gesellschaft

Gebrauchsinfos – Mundipharma

Mundipharma Deutschland GmbH & Co. KG DeSaintExupéryStrae 10 Frankfurt am Main. TEL +49 69 50 60 FAX +49 69 50 60 MAIL

hot articles